Minerva Biotechnologies

Minerva Biotechnologies

Biotechnology, 40 Bear Hill Rd, Waltham, Massachusetts, 02451, United States, 11-50 Employees

minervabio.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 78********

Who is MINERVA BIOTECHNOLOGIES

Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04...

Read More

map
  • 40 Bear Hill Rd, Waltham, Massachusetts, 02451, United States Headquarters: 40 Bear Hill Rd, Waltham, Massachusetts, 02451, United States
  • 1999 Date Founded: 1999
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from MINERVA BIOTECHNOLOGIES

Minerva Biotechnologies Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Minerva Biotechnologies

Answer: Minerva Biotechnologies's headquarters are located at 40 Bear Hill Rd, Waltham, Massachusetts, 02451, United States

Answer: Minerva Biotechnologies's phone number is 78********

Answer: Minerva Biotechnologies's official website is https://minervabio.com

Answer: Minerva Biotechnologies's revenue is $1 Million to $5 Million

Answer: Minerva Biotechnologies's SIC: 2834

Answer: Minerva Biotechnologies's NAICS: 541715

Answer: Minerva Biotechnologies has 11-50 employees

Answer: Minerva Biotechnologies is in Biotechnology

Answer: Minerva Biotechnologies contact info: Phone number: 78******** Website: https://minervabio.com

Answer: Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minervas first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access